Inhibition of human lung cancer cell growth by angiotensin-(1-7)

Patricia E Gallagher1, E Ann Tallant

  • 1The Hypertension and Vascular Disease Center, Wake Forest University School of Medicine, Winston-Salem, NC 27157-1032, USA. pgallagh@wfubmc.edu

Carcinogenesis
|July 31, 2004
PubMed

Insights

Angiotensin-(1-7) [Ang-(1-7)] effectively inhibits lung cancer cell growth by reducing DNA synthesis and ERK pathway activation. This peptide hormone shows potential as a novel chemotherapeutic and chemopreventive agent for lung cancer.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Angiotensin-(1-7) [Ang-(1-7)] is an endogenous peptide hormone within the renin-angiotensin system.
  • Ang-(1-7) exhibits known vasodilator and anti-proliferative properties.
  • Lung cancer remains a significant global health concern, necessitating novel therapeutic strategies.

Purpose of the Study:

  • To investigate the potential of Ang-(1-7) in inhibiting the growth of human lung cancer cells.
  • To elucidate the mechanism underlying the anti-proliferative effects of Ang-(1-7).

Main Methods:

  • Human lung cancer cell lines (SK-LU-1, A549, SK-MES-1) were treated with serum and Ang-(1-7).
  • Cell proliferation and DNA synthesis were assessed using various assays.
  • Receptor antagonist studies and Western blotting for ERK phosphorylation were performed.

Main Results:

  • Ang-(1-7) significantly reduced serum-stimulated growth and DNA synthesis in all tested lung cancer cell lines.
  • The anti-proliferative effect was mediated by the MAS receptor, not AT(1) or AT(2) receptors.
  • Ang-(1-7) inhibited ERK1/ERK2 phosphorylation, suggesting involvement of this signaling pathway.

Conclusions:

  • Angiotensin-(1-7) demonstrates selective and potent anti-proliferative effects on lung cancer cells.
  • The MAS receptor and ERK signaling pathway are implicated in Ang-(1-7)'s mechanism of action.
  • Ang-(1-7) represents a promising candidate for novel lung cancer chemotherapeutic and chemopreventive treatments.